Oral medicines that remove CBP and p300 to fight prostate and other cancers
Orally active CBP/p300 degraders
Creating new oral drugs that break down two proteins (CBP and p300) that help prostate and other tumors grow.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11294285 on NIH RePORTER |
What this research studies
This project is designing small oral drugs that cause the cancer-supporting proteins CBP and p300 to be destroyed inside tumor cells. So far the team has seen strong tumor shrinkage in lab-grown cancer cells and in mice with good oral absorption and tolerability. The researchers will optimize these compounds for safety and dosing with the goal of moving the best candidates toward human testing. If those steps go well, people with certain prostate or other cancers might be invited to clinical trials in the future.
Who could benefit from this research
Good fit: Future trials would likely target people with prostate cancer or other tumors driven by CBP/p300 activity, particularly those whose disease no longer responds to standard therapies.
Not a fit: Patients whose cancers are not driven by CBP/p300 or who need immediate standard-of-care treatment are unlikely to benefit from this preclinical work in the near term.
Why it matters
Potential benefit: If successful, this work could produce a new oral cancer treatment that shrinks tumors by removing proteins cancers rely on to grow.
How similar studies have performed: Related 'protein degrader' drugs have shown encouraging results in labs and early clinical tests for other targets, but CBP/p300 degraders are a newer approach that remains mostly preclinical.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Wang, Shaomeng — University of Michigan at Ann Arbor
- Study coordinator: Wang, Shaomeng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.